Journal
LUPUS
Volume 23, Issue 12, Pages 1313-1316Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203314544534
Keywords
Antiphospholipid syndrome; antiphospholipid antibodies; negatively charged phospholipids
Categories
Funding
- ARUP Institute of Clinical and Experimental Pathology
- Department of Pathology, University of Utah Salt Lake City
Ask authors/readers for more resources
The presence of lupus anticoagulant, moderate-to-high levels of IgG and/or IgM antibodies to beta-2 glycoprotein I or cardiolipin in association with at least one of the two major clinical manifestations (thrombosis and/or pregnancy-related morbidity) are required for a diagnosis of definite antiphospholipid syndrome (APS). The realization that certain negatively charged phospholipid (PL) autoantibodies broadly react with antibodies directed against cardiolipin and may be more reliable and specific markers for APS has led to the search for diagnostic assays with greater predictability for disease evaluation and management. This review focuses on the state-of-the-art analytical and clinical performance of IgG and IgM antibodies directed against negatively charged PLs, specifically phosphatidic acid (aPA), phosphatidylinositol (aPI), and phosphatidylserine (aPS), as well as the APhL assay, which contains a proprietary mixture of phospholipid antigens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available